Bajaj Healthcare Ltd
Incorporated in 1993, Bajaj Healthcare Ltd manufactures a wide range of Active Pharmaceutical Ingredients and Formulations[1]
- Market Cap ₹ 1,245 Cr.
- Current Price ₹ 394
- High / Low ₹ 745 / 379
- Stock P/E 24.3
- Book Value ₹ 154
- Dividend Yield 0.25 %
- ROCE 11.4 %
- ROE 10.7 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
Cons
- Stock is trading at 2.56 times its book value
- The company has delivered a poor sales growth of 5.76% over past five years.
- Company has a low return on equity of 4.15% over last 3 years.
- Dividend payout has been low at 3.71% of profits over last 3 years
- Company has high debtors of 169 days.
- Promoter holding has decreased over last 3 years: -8.11%
- Working capital days have increased from 55.6 days to 140 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 205 | 218 | 223 | 231 | 327 | 370 | 410 | 657 | 680 | 646 | 473 | 543 | 574 | |
| 186 | 189 | 193 | 200 | 288 | 327 | 362 | 521 | 561 | 534 | 397 | 460 | 489 | |
| Operating Profit | 19 | 29 | 30 | 31 | 39 | 43 | 48 | 136 | 119 | 112 | 76 | 83 | 85 |
| OPM % | 9% | 13% | 14% | 13% | 12% | 12% | 12% | 21% | 17% | 17% | 16% | 15% | 15% |
| 0 | 0 | 0 | 2 | 2 | 1 | 7 | 7 | 1 | -19 | -105 | 16 | 13 | |
| Interest | 7 | 8 | 8 | 8 | 8 | 8 | 7 | 8 | 13 | 18 | 30 | 28 | 22 |
| Depreciation | 9 | 9 | 9 | 11 | 11 | 11 | 12 | 16 | 18 | 17 | 28 | 28 | 27 |
| Profit before tax | 3 | 12 | 14 | 14 | 23 | 24 | 36 | 119 | 90 | 58 | -86 | 43 | 49 |
| Tax % | 40% | 37% | 39% | 43% | 33% | 33% | 30% | 30% | 20% | 25% | -3% | 7% | |
| 2 | 8 | 8 | 8 | 15 | 16 | 25 | 83 | 71 | 43 | -84 | 40 | 46 | |
| EPS in Rs | 2.19 | 8.34 | 3.04 | 2.83 | 5.50 | 5.91 | 9.14 | 30.11 | 25.87 | 15.59 | -30.36 | 12.51 | 14.52 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 5% | 0% | 0% | 5% | 6% | 6% | -3% | 8% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 6% |
| 3 Years: | -7% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 10% |
| 3 Years: | -18% |
| TTM: | 50% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | -1% |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 13% |
| 3 Years: | 4% |
| Last Year: | 11% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 7 | 7 | 7 | 7 | 14 | 14 | 14 | 14 | 14 | 16 | 16 |
| Reserves | 28 | 78 | 82 | 92 | 107 | 122 | 164 | 245 | 315 | 354 | 265 | 450 | 471 |
| 72 | 70 | 81 | 75 | 87 | 81 | 91 | 181 | 257 | 415 | 333 | 223 | 238 | |
| 43 | 38 | 39 | 45 | 68 | 57 | 74 | 86 | 136 | 115 | 154 | 144 | 114 | |
| Total Liabilities | 145 | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 833 | 839 |
| 56 | 108 | 130 | 128 | 127 | 128 | 162 | 208 | 270 | 366 | 253 | 238 | 251 | |
| CWIP | 3 | 1 | 1 | 0 | 2 | 1 | 5 | 57 | 52 | 22 | 7 | 3 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| 87 | 79 | 78 | 91 | 140 | 137 | 170 | 260 | 399 | 510 | 506 | 591 | 582 | |
| Total Assets | 145 | 189 | 209 | 219 | 268 | 267 | 343 | 526 | 721 | 898 | 765 | 833 | 839 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17 | 28 | 25 | 22 | 17 | 25 | 21 | 44 | 1 | -22 | 92 | 22 | |
| -9 | -17 | -31 | -8 | -12 | -13 | -28 | -109 | -75 | -93 | -11 | -15 | |
| -8 | -11 | 5 | -13 | 2 | -13 | 3 | 75 | 62 | 131 | -97 | -6 | |
| Net Cash Flow | 1 | -0 | -0 | 0 | 7 | -0 | -4 | 10 | -12 | 16 | -16 | 0 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 98 | 86 | 70 | 83 | 90 | 77 | 88 | 55 | 99 | 110 | 139 | 169 |
| Inventory Days | 51 | 50 | 56 | 45 | 57 | 45 | 54 | 94 | 143 | 199 | 206 | 206 |
| Days Payable | 68 | 63 | 46 | 51 | 74 | 45 | 80 | 67 | 94 | 81 | 128 | 122 |
| Cash Conversion Cycle | 81 | 73 | 80 | 78 | 73 | 77 | 62 | 82 | 148 | 228 | 217 | 254 |
| Working Capital Days | -25 | -11 | -17 | -4 | 0 | 12 | 24 | 34 | 40 | 27 | -0 | 140 |
| ROCE % | 10% | 16% | 13% | 13% | 16% | 16% | 18% | 36% | 20% | 14% | 8% | 11% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
2d - Appointment of Umeshkumar L. Bhavsar as Independent Director from Jan 13, 2026 to Jan 12, 2031 (subject to shareholder approval).
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 12 Jan
-
Board Meeting Intimation for Consideration Of Financial Results
12 Jan - Board meeting Jan 16, 2026 to approve Q3/9M unaudited results; trading window closed.
-
Announcement under Regulation 30 (LODR)-Change in Management
5 Jan - Appointed Purnima Dhanraj Amin as independent director, Jan 05, 2026–Jan 04, 2031, subject to shareholders' approval.
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
31 Dec - CDSCO approved on Dec 31, 2025 to conduct clinical trial and bioequivalence study of Suvorexant tablets.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1][2][3]
BHL is focused on development, supply, manufacturing of Amino Acids, Nutritional Supplements and Active Pharma Ingredients for Pharmaceutical, Nutraceuticals and Food industries. It manufactures active pharmaceutical ingredients and formulations in the form of tablets, capsules, powder, etc. for ~550+ clients, exporting bulk drugs to ~62+ countries in Europe, USA, Africa, Australia, etc.